Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 47 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 921

Topic: Biology, Genetics & Bone Healing
Osteoclasts are multinucleated giant cells that create a sealed zone to isolate the resorptive pit (Howship's lacuna) on the bone surface. Which of the following integrins is primarily responsible for forming this sealing zone by binding to osteopontin and bone sialoprotein?
. Alpha-5 Beta-1
. Alpha-V Beta-3
. Alpha-2 Beta-1
. Alpha-M Beta-2
. Alpha-L Beta-2

Correct Answer & Explanation

. Alpha-V Beta-3

Explanation

The alpha-v beta-3 (αvβ3) integrin is highly expressed on the osteoclast cell membrane. It binds specifically to RGD (Arg-Gly-Asp) amino acid sequences found in bone matrix proteins like osteopontin and bone sialoprotein. This interaction is essential for the tight attachment of the osteoclast to the bone and the formation of the actin sealing zone.

Question 922

Topic: Biology, Genetics & Bone Healing

Recombinant human bone morphogenetic protein-2 (rhBMP-2) is used off-label in various nonunion surgeries. Following the binding of rhBMP-2 to its transmembrane serine/threonine kinase receptors, which of the following intracellular signaling pathways is primarily activated to upregulate osteogenic gene expression?

. Wnt/beta-catenin pathway
. Smad 1/5/8 pathway
. JAK/STAT pathway
. MAPK/ERK pathway
. Notch/Hes pathway

Correct Answer & Explanation

. Smad 1/5/8 pathway

Explanation

Bone morphogenetic proteins (BMPs) belong to the TGF-beta superfamily. When BMPs bind to their specific heterodimeric receptors, they primarily signal through the canonical Smad pathway, specifically phosphorylating Smad 1, 5, and 8. These complex with Smad 4 and translocate to the nucleus to induce transcription of osteoblastic genes like Runx2.

Question 923

Topic: Biology, Genetics & Bone Healing

Demineralized bone matrix (DBM) is commonly used as a bone graft extender in orthopedic surgery. Which of the following best describes its primary biologic properties?

. Osteogenic and osteoconductive
. Osteoinductive and osteoconductive
. Osteogenic only
. Osteoconductive only
. Osteoinductive only

Correct Answer & Explanation

. Osteoinductive and osteoconductive

Explanation

Demineralized bone matrix (DBM) is osteoinductive (due to the release of bone morphogenetic proteins [BMPs] during the acid demineralization process) and osteoconductive (providing a collagen scaffold for bone growth). It is not osteogenic, because the sterilization and processing steps destroy all viable cells (osteoblasts and osteoprogenitor cells).

Question 924

Topic: Biology, Genetics & Bone Healing

In bone biology, the Wnt signaling pathway is crucial for osteoblastogenesis and bone formation. Sclerostin is a key negative regulator of this pathway. By binding to which of the following receptors does sclerostin exert its inhibitory effect?

. RANKL
. Osteoprotegerin
. LRP5/LRP6 coreceptors
. Runx2
. Bone morphogenetic protein 2 (BMP-2)

Correct Answer & Explanation

. LRP5/LRP6 coreceptors

Explanation

Sclerostin, a glycoprotein secreted primarily by osteocytes, acts as a potent inhibitor of the canonical Wnt signaling pathway. It does so by binding to the LRP5 and LRP6 coreceptors on the osteoblast surface, preventing Wnt ligands from binding. This inhibition reduces intracellular accumulation of beta-catenin, thereby decreasing bone formation. Monoclonal antibodies targeting sclerostin (e.g., romosozumab) exploit this mechanism to treat osteoporosis.

Question 925

Topic: Biology, Genetics & Bone Healing

Recombinant human bone morphogenetic protein-2 (rhBMP-2) stimulates osteoblastic differentiation primarily through binding to cell surface serine/threonine kinase receptors. Upon activation, which intracellular signaling molecules are phosphorylated and translocated to the nucleus to regulate gene transcription?

. JAK and STAT proteins
. Smad 1, 5, and 8
. NF-kappaB and IKK
. Wnt and beta-catenin
. ERK and MAPK

Correct Answer & Explanation

. Smad 1, 5, and 8

Explanation

Bone Morphogenetic Proteins (BMPs) signal through cell surface serine/threonine kinase receptors. Once bound, they phosphorylate receptor-regulated Smads (R-Smads), specifically Smads 1, 5, and 8. These complex with Smad 4 to translocate to the nucleus and upregulate osteogenic genes like Runx2.

Question 926

Topic: Biology, Genetics & Bone Healing

Demineralized Bone Matrix (DBM) is widely used in orthopedic surgery as a bone graft substitute. DBM primarily facilitates bone healing by providing which of the following biological properties?

. Osteogenesis and Osteoconduction
. Osteoinduction and Osteoconduction
. Osteogenesis only
. Structural mechanical support
. Osteopromotion via viable mesenchymal stem cells

Correct Answer & Explanation

. Osteoinduction and Osteoconduction

Explanation

Demineralized bone matrix (DBM) is created by acid extraction of allograft bone, leaving a collagenous matrix (which provides osteoconduction) and exposing naturally occurring growth factors like Bone Morphogenetic Proteins (BMPs) (which provide osteoinduction). DBM has no living cells, so it is not osteogenic, and its processing removes its structural/mechanical integrity.

Question 927

Topic: Biology, Genetics & Bone Healing
Which of the following bone morphogenetic proteins (BMPs) is actually a procollagen C-proteinase and does not belong to the transforming growth factor-beta (TGF-beta) superfamily?
. BMP-1
. BMP-2
. BMP-4
. BMP-7
. BMP-9

Correct Answer & Explanation

. BMP-1

Explanation

BMP-1 is unique among the bone morphogenetic proteins. While initially discovered alongside other BMPs, it was later identified as a metalloproteinase (specifically a procollagen C-proteinase) that facilitates cartilage and bone formation by cleaving the C-termini of procollagens I, II, and III. Unlike BMP-2, BMP-4, and BMP-7 (which are osteoinductive factors), BMP-1 does not belong to the TGF-beta superfamily and does not signal through SMAD pathways.

Question 928

Topic: Biology, Genetics & Bone Healing

A 25-year-old female presents with a painful, lucent, eccentrically located lesion in the distal femur metaphysis extending to the subchondral bone. Biopsy reveals a population of neoplastic mononuclear cells and reactive multinucleated giant cells. Which of the following describes the mechanism of action of the targeted medical therapy (Denosumab) used for severe or recurrent cases of this condition?

. Inhibiting the RANK receptor directly on the surface of osteoblasts
. Binding to RANKL to prevent the activation and differentiation of osteoclast-like cells
. Directly inducing apoptosis of the multinucleated giant cells via p53 pathways
. Inhibiting vascular endothelial growth factor (VEGF) to reduce tumor vascularity
. Stimulating osteoprotegerin (OPG) production by the neoplastic mononuclear cells

Correct Answer & Explanation

. Binding to RANKL to prevent the activation and differentiation of osteoclast-like cells

Explanation

Giant Cell Tumor (GCT) of bone is characterized by neoplastic mononuclear stromal cells that express high levels of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). This recruits and activates reactive multinucleated giant cells (osteoclasts) that cause bone destruction. Denosumab is a humanized monoclonal antibody that binds to RANKL, preventing its interaction with the RANK receptor on the osteoclast precursor cells, thereby inhibiting their differentiation and activation.

Question 929

Topic: Biology, Genetics & Bone Healing

Which of the following cytokines is most directly responsible for the final activation of osteoclasts in the pathogenesis of aseptic loosening secondary to polyethylene wear debris?

. Interleukin-1 (IL-1)
. Tumor Necrosis Factor-alpha (TNF-alpha)
. Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL)
. Osteoprotegerin (OPG)
. Bone Morphogenetic Protein-2 (BMP-2)

Correct Answer & Explanation

. Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL)

Explanation

While macrophages phagocytose particulate wear debris and release inflammatory mediators such as IL-1, IL-6, and TNF-alpha, these cytokines act to stimulate osteoblasts and other local cells to express RANKL. RANKL then binds to RANK on the surface of osteoclast precursors, representing the final direct and necessary step for osteoclast differentiation, activation, and subsequent bone resorption (osteolysis).

Question 930

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with knee pain. Radiographs reveal an eccentric, lytic, epiphyseal-metaphyseal lesion of the distal femur extending to the subchondral bone without a sclerotic rim. Biopsy shows multinucleated giant cells and mononuclear stromal cells. If treating with Denosumab, what is the precise cellular target of the drug?

. VEGF on endothelial cells
. RANKL produced by mononuclear stromal cells
. RANK receptor on multinucleated giant cells
. RANKL produced by multinucleated giant cells
. RANK receptor on mononuclear stromal cells

Correct Answer & Explanation

. RANKL produced by mononuclear stromal cells

Explanation

In Giant Cell Tumor (GCT) of bone, the actual neoplastic cells are the mononuclear spindle-like stromal cells. These cells express excess RANK Ligand (RANKL). This RANKL binds to the RANK receptors on the non-neoplastic multinucleated giant cells (which are osteoclast-like), recruiting them and causing massive bone resorption. Denosumab is a monoclonal antibody that targets and binds RANKL, effectively halting this destructive process.

Question 931

Topic: Biology, Genetics & Bone Healing
During secondary fracture healing, the process transitions through several distinct phases. Which type of collagen is synthesized primarily during the soft callus (cartilaginous) phase?
. Type I collagen
. Type II collagen
. Type III collagen
. Type IV collagen
. Type X collagen

Correct Answer & Explanation

. Type II collagen

Explanation

Secondary fracture healing relies on endochondral ossification. During the soft callus phase, chondrocytes proliferate and synthesize a cartilaginous matrix rich in Type II collagen. Later, during the hard callus phase, these chondrocytes hypertrophy (secreting Type X collagen) and undergo apoptosis, while osteoblasts move in and deposit woven bone, which is primarily Type I collagen.

Question 932

Topic: Biology, Genetics & Bone Healing

Denosumab is highly effective in the treatment of unresectable or recurrent Giant Cell Tumor of bone (GCT). What is its precise mechanism of action?

. Binds directly to the RANK receptor on osteoclasts, inhibiting their activation
. Binds to RANK Ligand (RANKL), preventing its interaction with the RANK receptor
. Inhibits the osteoclast proton pump, preventing an acidic resorption environment
. Cross-links DNA in the multinucleated osteoclast-like giant cells
. Inhibits matrix metalloproteinases in the neoplastic mononuclear stroma

Correct Answer & Explanation

. Binds to RANK Ligand (RANKL), preventing its interaction with the RANK receptor

Explanation

Denosumab is a fully human monoclonal antibody that specifically binds to RANK Ligand (RANKL), which is overexpressed by the mononuclear neoplastic stromal cells of GCT. By binding RANKL, denosumab prevents it from activating the RANK receptor on the reactive osteoclast-like giant cells, thereby halting bone resorption and tumor progression.

Question 933

Topic: Biology, Genetics & Bone Healing

Giant Cell Tumor (GCT) of bone is a locally aggressive benign tumor. Which of the following accurately describes the cellular pathophysiology and the targeted mechanism of the biological agent Denosumab in treating this condition?

. The neoplastic multinucleated giant cells express RANK, which is inhibited by Denosumab
. The neoplastic mononuclear stromal cells express RANKL; Denosumab is a monoclonal antibody against RANKL
. The neoplastic osteoblasts express osteoprotegerin (OPG); Denosumab binds and neutralizes OPG
. The neoplastic macrophages express TNF-alpha; Denosumab acts as a TNF-alpha inhibitor
. The neoplastic spindle cells express VEGF; Denosumab inhibits angiogenesis via VEGF blockade

Correct Answer & Explanation

. The neoplastic mononuclear stromal cells express RANKL; Denosumab is a monoclonal antibody against RANKL

Explanation

In Giant Cell Tumor (GCT) of bone, the actual neoplastic cells are the mononuclear spindle-like stromal cells. These cells express high levels of RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). The multinucleated giant cells are reactive (osteoclast-like) and express RANK. Denosumab is a human monoclonal antibody that binds and inhibits RANKL, effectively halting the recruitment and activation of the destructive giant cells.

Question 934

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with a biologically active Giant Cell Tumor (GCT) of the distal femur. She is scheduled for curettage but is treated preoperatively with Denosumab to consolidate the tumor margins. What is the mechanism of action of this medication?

. Direct cytotoxicity to the neoplastic mononuclear cells
. Monoclonal antibody that binds and inhibits RANKL
. Inhibition of vascular endothelial growth factor (VEGF)
. Stimulation of osteoblast proliferation and bone formation
. Matrix metalloproteinase (MMP) inhibitor

Correct Answer & Explanation

. Monoclonal antibody that binds and inhibits RANKL

Explanation

Denosumab is a fully human monoclonal antibody that binds to Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). By inhibiting RANKL, it prevents the activation of the RANK receptor on osteoclast-like giant cells, thereby profoundly reducing osteolysis and promoting ossification of the tumor matrix.

Question 935

Topic: Biology, Genetics & Bone Healing
Which type of collagen is the predominant structural protein found in the extracellular matrix of normal mature articular (hyaline) cartilage?
. Type I collagen
. Type II collagen
. Type III collagen
. Type IV collagen
. Type X collagen

Correct Answer & Explanation

. Type II collagen

Explanation

Type II collagen makes up 90-95% of the collagen in normal articular (hyaline) cartilage, providing tensile strength. Type I is found in bone, tendon, and fibrocartilage (such as the meniscus or scar cartilage). Type X is specific to the hypertrophic zone of the growth plate during endochondral ossification.

Question 936

Topic: Biology, Genetics & Bone Healing

A 35-year-old female presents with a destructive radiolucent lesion in the distal femur. Core needle biopsy confirms Giant Cell Tumor of bone. Multidisciplinary tumor board recommends neoadjuvant treatment with Denosumab prior to intralesional curettage. Denosumab targets which of the following cellular mechanisms in this specific tumor?

. Direct induction of apoptosis in the multinucleated giant cells
. Inhibition of RANKL produced by the neoplastic mononuclear stromal cells
. Neutralization of RANK receptors on the surface of osteoclast precursors
. Inhibition of VEGF-mediated tumor angiogenesis
. Blockade of the Wnt/beta-catenin signaling pathway

Correct Answer & Explanation

. Inhibition of RANKL produced by the neoplastic mononuclear stromal cells

Explanation

Giant Cell Tumor of bone consists of neoplastic mononuclear stromal cells and reactive multinucleated giant cells (osteoclast-like cells). The neoplastic stromal cells overexpress RANKL, which recruits and activates the osteoclast-like giant cells, leading to bone destruction. Denosumab is a monoclonal antibody that binds to and inhibits RANKL produced by the stromal cells, thereby preventing the activation of the destructive giant cells.

Question 937

Topic: Biology, Genetics & Bone Healing

During the process of secondary fracture healing (enchondral ossification), woven bone is gradually replaced by strong, organized lamellar bone. This critical transition primarily occurs during which stage of the fracture healing cascade?

. Inflammatory phase
. Soft callus formation phase
. Hard callus formation phase
. Remodeling phase
. Hematoma organization phase

Correct Answer & Explanation

. Remodeling phase

Explanation

Secondary fracture healing consists of hematoma/inflammation, soft callus (cartilage), hard callus (woven bone), and remodeling. The transition from random, disorganized woven bone (formed during the hard callus phase) to highly organized, stress-aligned lamellar bone occurs strictly during the remodeling phase, governed by osteoclast and osteoblast activity acting under Wolff's law.

Question 938

Topic: Biology, Genetics & Bone Healing

During bone remodeling, osteoclasts resorb bone by creating an acidic microenvironment to dissolve hydroxyapatite and by secreting enzymes to degrade the organic bone matrix. Which of the following enzymes is primarily responsible for the cleavage and degradation of Type I collagen in the osteoclast resorption pit (Howship's lacuna)?

. Alkaline phosphatase
. Matrix metalloproteinase-9
. Tartrate-resistant acid phosphatase (TRAP)
. Carbonic anhydrase II
. Cathepsin K

Correct Answer & Explanation

. Cathepsin K

Explanation

Cathepsin K is a lysosomal cysteine protease secreted by osteoclasts. It is the primary enzyme responsible for the degradation of Type I collagen and other noncollagenous proteins in the organic matrix of bone. Carbonic anhydrase II produces the protons needed to dissolve the mineral component. TRAP is a marker of osteoclast activity but does not cleave collagen. Alkaline phosphatase is produced by osteoblasts.

Question 939

Topic: Biology, Genetics & Bone Healing

Romosozumab has been introduced for the treatment of severe osteoporosis. What is the precise cellular mechanism of action of this monoclonal antibody?

. Binds to RANKL, inhibiting osteoclast activation
. Stimulates the parathyroid hormone (PTH) receptor
. Inhibits sclerostin, leading to upregulation of the Wnt/beta-catenin signaling pathway
. Binds to Cathepsin K, preventing bone matrix degradation
. Stimulates Osteoprotegerin (OPG) production by osteoblasts

Correct Answer & Explanation

. Inhibits sclerostin, leading to upregulation of the Wnt/beta-catenin signaling pathway

Explanation

Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin. Sclerostin is an endogenous inhibitor of the Wnt/beta-catenin signaling pathway produced by osteocytes. By inhibiting sclerostin, Romosozumab promotes Wnt signaling, which significantly increases bone formation (anabolic effect) and also decreases bone resorption.

Question 940

Topic: Biology, Genetics & Bone Healing

A 29-year-old female presents with knee pain. Radiographs reveal an eccentric, lytic, expansile lesion in the distal femoral epiphysis extending to the subchondral bone. Biopsy confirms Giant Cell Tumor of Bone (GCT). If medical management is considered prior to surgery, what is the mechanism of action of the preferred targeted therapeutic agent (Denosumab)?

. Monoclonal antibody that binds and inhibits RANKL
. Tyrosine kinase inhibitor targeting VEGF receptors
. Monoclonal antibody targeting osteoclast integrins
. Direct inhibitor of osteoblast apoptosis
. Bisphosphonate that incorporates into the bone matrix

Correct Answer & Explanation

. Monoclonal antibody that binds and inhibits RANKL

Explanation

Denosumab is a fully human monoclonal antibody that binds to Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), preventing RANKL from activating RANK on the surface of osteoclasts and their precursors. In Giant Cell Tumor of bone, the neoplastic mononuclear cells express RANKL, which recruits reactive osteoclast-like giant cells that cause bone destruction. Denosumab blocks this process.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page